ASCO 2020: AZ’s Tagrisso Sails Into Early-Stage NSCLC On ‘Momentous’ ADAURA Trial Data

83% Reduction In Disease Recurrence Or Death

A highly impressive improvement in disease-free survival in ADAURA is set to pitch AstraZeneca’s best-selling product into a new untapped market, early-stage EGFRm NSCLC, reaping a possible $3bn in extra sales.

Lung_Cancer_Cells — • Source: Shutterstock

AstraZeneca PLC’s top-selling drug Tagrisso (osimertinib) cut the risk of disease recurrence or death by 83% in patients with early stage EGFR mutant non–small cell lung cancer at two years, the first data from the Phase III ADAURA study show.

The initial trial findings, reported at this year’s virtual American Society of Clinical Oncology meeting, offer AstraZeneca a new swathe of patients in the EGFR mutated NSCLC market, where the product already enjoys blockbuster sales in two metastatic treatment settings

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Affimed’s ASCO ‘Hail Mary’ As Survival Chances Slim

20 May 2025

• By Kevin Grogan

The German biotech has been forced into insolvency and NASDAQ suspension.

Merck’s Welireg Adrenal Tumor Rollout Targets Specialized Centers

15 May 2025

• By Alaric DeArment

The drugmaker won US FDA approval for the HIF-2α inhibitor in pheochromocytoma and paraganglioma, a rare cancer of the adrenal glands, in adolescents and adults.

China Biopharma Podcast

14 May 2025

• By Dexter Jie Yan and Xu Hu

Join our China-based editors Dexter Yan and Xu Hu in this Chinese-language podcast looking at some of their recent interviews and other key coverage.

iTeos/GSK To Terminate Collaboration After TIGIT Trials Flop

13 May 2025

• By Alaric DeArment

Belrestotug is the latest anti-TIGIT candidate to fail to meet expectations. iTeos said it will pursue strategic alternatives.

Apnimed’s AD109 Could Be A Wake-Up Call For Sleep Apnea Market

19 May 2025

• By Joseph Haas

The first of two Phase III trials in obstructive sleep apnea showed Apnimed’s combination pill can offer a therapeutic alternative to entrenched CPAP devices.